<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833805</url>
  </required_header>
  <id_info>
    <org_study_id>J1688</org_study_id>
    <secondary_id>IRB00107139</secondary_id>
    <nct_id>NCT02833805</nct_id>
  </id_info>
  <brief_title>NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia</brief_title>
  <official_title>A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary objective is to determine if it is feasible for previously untreated severe&#xD;
      aplastic anemia (SAA) patients to be transplanted using non-myeloablative conditioning and&#xD;
      post transplantation cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical trial of upfront bone marrow transplantation for patients with SAA who do&#xD;
      not have a fully human leukocyte antigen (HLA) matched donor. The trial uses a conditioning&#xD;
      regimen which has been successful in the refractory and relapsed setting to maximize&#xD;
      engraftment and post transplant therapy to minimize graft versus host disease (GVHD). This&#xD;
      would be used here in patients who have not yet undergone immunosuppressive therapy for their&#xD;
      SAA or are thought to be unlikely to respond to immunosuppressive therapy for SAA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 2021</completion_date>
  <primary_completion_date type="Actual">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival and engraftment at one year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of enrolled participants who receive BMT, achieve engraftment, and are alive at one year post BMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at one year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants alive at one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of neutrophil recovery</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who have recovered neutrophil counts at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of platelet recovery</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who have recovered platelet counts at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience primary graft failure by one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary graft failure</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience secondary graft failure by one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades II-IV acute GVHD, Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>Percentage of participants who experience grade II, III, or IV acute GVHD by Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades III-IV acute GVHD, Day 100</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience grade III or IV acute GVHD by Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, one year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience chronic GVHD by one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate full donor chimerism</measure>
    <time_frame>Day 60</time_frame>
    <description>Percentage of participants with full donor chimerism at Day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate GVHD-free relapse-free survival (GRFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants alive, without relapse, and without GVHD at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate transplant-related mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants deceased for reasons related to BMT at 1 year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>Anti-thymocyte globulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Days -6 through -2: 30 mg/m^2 IV daily</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Cy</other_name>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>Day -1: 200 centigray (cGy) in a single fraction</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Start on Day 5 through Day 365</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>FK506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of inherited or acquired severe aplastic anemia (SAA)&#xD;
&#xD;
          -  One of the following available donors:&#xD;
&#xD;
               1. HLA-haploidentical relative&#xD;
&#xD;
               2. If recipient is &gt;= 40 years old, may use HLA-matched related donor&#xD;
&#xD;
               3. For recipients with inherited bone marrow failure syndromes (IBMFS) with clear&#xD;
                  evidence of same disorder in potential related donors, may use 10/10 matched&#xD;
                  unrelated donor&#xD;
&#xD;
          -  Recipient and/or legal guardian must sign protocol informed consent&#xD;
&#xD;
          -  Donor must be willing to donate bone marrow&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 40%. For recipients &lt; 13 years old,&#xD;
             shortening fraction &gt;= 26% may be used instead.&#xD;
&#xD;
          -  Bilirubin &lt; 3 x upper limit of normal (ULN) for age, unless patient has Gilbert's&#xD;
             disease&#xD;
&#xD;
          -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 5 x ULN for age&#xD;
&#xD;
          -  For patients &gt;= 13 years old: estimated creatinine clearance &gt; 50 mL/min using&#xD;
             Cockcroft-Gault formula and actual body weight&#xD;
&#xD;
          -  For patients &gt;= 1 but &lt; 13 years old: glomerular filtration rate (GFR) estimated by&#xD;
             updated Schwartz formula &gt;= 90 mL/min/1.73 m^2. If estimated GFR is &lt; 90 mL/min/1.73&#xD;
             m^2, 24-hour measured creatinine clearance must be &gt; 50 mL/min/1.73 m^2.&#xD;
&#xD;
          -  For patients &gt;= 8 years old, diffusing capacity of the lung for carbon monoxide (DLCO)&#xD;
             (corrected for hemoglobin) &gt; 40%; forced expiratory volume at one second (FEV1) &gt; 50%;&#xD;
             forced vital capacity (FVC) &gt; 50%&#xD;
&#xD;
          -  For patients &lt; 8 years old or unable to undergo pulmonary function testing: no&#xD;
             evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation &gt; 92%&#xD;
             on room air&#xD;
&#xD;
          -  Karnofsky/Lansky status (depending on age) &gt;= 70%&#xD;
&#xD;
          -  Females and males of childbearing potential must agree to practice 2 effective methods&#xD;
             of contraception at the same time. If unwilling, they must agree to complete&#xD;
             abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous administration of immunosuppressive therapy for SAA.&#xD;
&#xD;
          -  Fanconi anemia. At minimum, this diagnosis must be excluded by diepoxybutane (DEB) or&#xD;
             equivalent testing on peripheral blood or marrow in patients &lt; 30 years old.&#xD;
&#xD;
          -  Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome&#xD;
             (pre-MDS) or MDS on bone marrow examination&#xD;
&#xD;
          -  Presence of anti-donor antibodies&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant&#xD;
&#xD;
          -  Prior solid organ transplant&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infection&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  Active hepatitis B or C infection determined by serology and/or nucleic acid testing&#xD;
             (NAT)&#xD;
&#xD;
          -  Pregnancy or active breastfeeding&#xD;
&#xD;
          -  Prior malignancies except: resected basal carcinoma or treated cervical carcinoma in&#xD;
             situ; cancer treated with curative intent &gt; 5 years previously. Other prior cancers&#xD;
             will not be allowed unless approved by the PI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy E DeZern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunosuppression</keyword>
  <keyword>nonmyeloablative</keyword>
  <keyword>non-myeloablative</keyword>
  <keyword>allogeneic</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>bone marrow</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>thymoglobulin</keyword>
  <keyword>ATG</keyword>
  <keyword>fludarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

